Although there is room for improvement, DCE-MRI using liposomal contrast agents such as Gd-L could be an important method to anticipate the extravasation of the liposomal anti-cancer drug during TβR-I inhibitor-combined therapy. This evidence concerns the gene TGFBR1 and cancer.